HIV therapy - Human Genome Sciences

Drug Profile

HIV therapy - Human Genome Sciences

Alternative Names: CCR5-mAb; CCR5mAb004; HGS 004; HGS 101

Latest Information Update: 17 Nov 2010

Price : $50

At a glance

  • Originator Human Genome Sciences
  • Class Monoclonal antibodies
  • Mechanism of Action CCR5 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 31 Dec 2008 Discontinued - Phase-I for HIV infections in USA (IV)
  • 17 Oct 2006 Data presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2006) have been added to the adverse events, pharmacokinetics, and Viral Infections therapeutic trials sections
  • 31 Mar 2005 Phase-I clinical trials in HIV infections treatment in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top